Allele loss in Wilms tumors of chromosome arms 11q, 16q, and 22q correlate with clinicopathological parameters
- PMID: 9669666
- DOI: 10.1002/(sici)1098-2264(199808)22:4<287::aid-gcc4>3.0.co;2-r
Allele loss in Wilms tumors of chromosome arms 11q, 16q, and 22q correlate with clinicopathological parameters
Abstract
An extended analysis for loss of heterozygosity (LOH) on eight chromosomes was conducted in a series of 82 Wilms tumors. Observed rates of allele loss were: 9.5% (1p), 5% (4q), 6% (6p), 3% (7p), 9.8% (11q), 28% (11p15), 13.4% (16q), 8.8% (18p), and 13.8% (22q). Known regions of frequent allele loss on chromosome arms 1p, 11p15, and 16q were analyzed with a series of markers, but their size could not be narrowed down to smaller intervals, making any positional cloning effort difficult. In contrast to most previous studies, several tumors exhibited allele loss for multiple chromosomes, suggesting an important role for genome instability in a subset of tumors. Comparison with clinical data revealed a possible prognostic significance, especially for LOH on chromosome arms 11q and 22q with high frequencies of anaplastic tumors, tumor recurrence, and fatal outcome. Similarly, LOH 16q was associated with anaplastic and recurrent tumors. These markers may be helpful in the future for selecting high-risk tumors for modified therapeutic regimens.
Similar articles
-
Loss of 11q and 16q in Wilms tumors is associated with anaplasia, tumor recurrence, and poor prognosis.Genes Chromosomes Cancer. 2007 Feb;46(2):163-70. doi: 10.1002/gcc.20397. Genes Chromosomes Cancer. 2007. PMID: 17099873
-
Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.J Clin Oncol. 2005 Oct 10;23(29):7312-21. doi: 10.1200/JCO.2005.01.2799. Epub 2005 Aug 29. J Clin Oncol. 2005. PMID: 16129848 Clinical Trial.
-
Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors.Mol Cancer Res. 2005 Sep;3(9):493-502. doi: 10.1158/1541-7786.MCR-05-0082. Mol Cancer Res. 2005. PMID: 16179496
-
Loss of heterozygosity mapping in Wilms tumor indicates the involvement of three distinct regions and a limited role for nondisjunction or mitotic recombination.Genes Chromosomes Cancer. 1992 Nov;5(4):326-34. doi: 10.1002/gcc.2870050408. Genes Chromosomes Cancer. 1992. PMID: 1283321 Review.
-
Genetic changes of two Wilms tumors with anaplasia and a review of the literature suggesting a marker profile for therapy resistance.Cancer Genet Cytogenet. 2002 Jun;135(2):128-38. doi: 10.1016/s0165-4608(01)00647-1. Cancer Genet Cytogenet. 2002. PMID: 12127397 Review.
Cited by
-
Wilms' tumour: a complex enigma to decipher.Clin Transl Oncol. 2008 Aug;10(8):457-61. doi: 10.1007/s12094-008-0233-6. Clin Transl Oncol. 2008. PMID: 18667375 Review.
-
Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group.J Clin Oncol. 2016 Sep 10;34(26):3189-94. doi: 10.1200/JCO.2015.66.1140. Epub 2016 Jul 11. J Clin Oncol. 2016. PMID: 27400937 Free PMC article.
-
In silico regulatory analysis for exploring human disease progression.Biol Direct. 2008 Jun 18;3:24. doi: 10.1186/1745-6150-3-24. Biol Direct. 2008. PMID: 18564415 Free PMC article.
-
Genetic and chromosomal alterations in Kenyan Wilms Tumor.Genes Chromosomes Cancer. 2015 Nov;54(11):702-15. doi: 10.1002/gcc.22281. Epub 2015 Aug 14. Genes Chromosomes Cancer. 2015. PMID: 26274016 Free PMC article.
-
Molecular Markers of Pediatric Solid Tumors-Diagnosis, Optimizing Treatments, and Determining Susceptibility: Current State and Future Directions.Cells. 2022 Apr 6;11(7):1238. doi: 10.3390/cells11071238. Cells. 2022. PMID: 35406801 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical